Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. (FHTX) Stock Overview
Explore Foghorn Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
271.5M
P/E Ratio
-3.87
EPS (TTM)
$-1.29
ROE
2.15%
FHTX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Foghorn Therapeutics Inc. (FHTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $5.25.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.87 and a market capitalization of 271.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Adrian H. B. Gottschalk
112
500 Technology Square, Cambridge, MA
2020